Patient Information

Patient Information

Source: European Reference Network

Systemic Lupus Erythematosus (SLE)
SLE is the paradigm of systemic autoimmune diseases characterized by a wide spectrum of clinical manifestations with an unpredictable relapsing-remitting course. SLE typically affects young women between 16 and 55 years and may involve almost all organs and tissues.

Some of the most common clinical features are: mucocutaneous lesions, articular manifestations, renal involvement, haematological disorders, serositis and fever. 40-70% of SLE patients present lupus nephritis (LN) whose dominant feature is proteinuria usually associated with urinary sediment abnormalities. In most severe cases LN may result in chronic renal failure.

Neuropsychiatric manifestations can also be present and they include several symptoms such as headache, seizure disorder, psychosis, acute confusional state and cognitive dysfunction. A higher rate of mortality and morbidity is described among patients with renal and neuropsychiatric involvement.

The serological picture of SLE is characterized by the positivity of many autoantibodies among which the most specific are anti-dsDNA and anti-Sm. The presence of antiphospholipid (aPL) antibodies in all SLE patients is associated with a worse prognosis. During SLE course patients may develop both disease- and treatment-related damage; although the better use of the available therapies has greatly improved SLE patients’ outcome, the disease is still associated with a significant morbidity.

For useful references, kindly refer to the European Reference Network:

Patient Organisations

Lupus Europe
Lupus Europe

Become part of our community
Click here to subscribe to our mailing list

twitter facebook linkedin linkedin youtube
Download Lupus Academy ‘Quick Facts
Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands
Tel: +31 416 693 925